Investor Presentation First Nine Months of 2022

7 Investor presentation First nine months of 2022 Novo NordiskⓇ International Operations diabetes care sales growth is driven by GLP-1 performance Reported Diabetes care sales and growth per IO geography DKK billion 9% 50 40 55% 30 30 GLP-1 patients and value market share in IO ■Insulin I GLP-1 Growth at CER Number of patients (millions) Value market share 5 Class growth >50% 75% 62.6% 60% 4 Geographical regions 3 12% 20 20 39% 2 -7% -9% 25% 10 87% 86% 1 -2% -21% 3% 0 0 IO EMEA China ROW Aug-20 Aug-21 GLP-1 patients -VictozaⓇ OzempicⓇ -dulaglutide 41.3% 45% 35.3% 30% 16.5% 15% 4.3% 0% RybelsusⓇ -NN GLP-1 Aug-22 Source: IQVIA MAT, Aug 2022 (Spot rate). Note that the market share and patient numbers are based on countries with IQVIA coverage. GLP-1 class growth calculated as Jun-Aug 2022 vs Jun-Aug 2021 (Rolling 3 month average) IO: International Operations; NN: Novo Nordisk; EMEA: Europe, Middle East and Africa; China: Mainland China, Hong Kong and Taiwan; Row: Rest of World; R3M: Rolling three months

View entire presentation